Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis
- PMID: 24475823
- DOI: 10.1148/radiol.13130940
Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis
Abstract
Purpose: To evaluate the long-term outcomes of radiofrequency ablation (RFA) as a first-line therapy for early-stage hepatocellular carcinoma (HCC) and determine the prognostic factors for survival.
Materials and methods: The institutional review board approved this retrospective study. From January 2006 to December 2007, 162 consecutive patients with cirrhosis (Child-Pugh class A and B, 137 and 25 patients, respectively) who underwent RFA as a first-line treatment for up to three HCCs with a maximum diameter of 5 cm (182 HCCs; mean diameter ± standard deviation, 2.59 cm ± 0.79; 17 multinodular forms) were included. After a mean follow-up of 50.3 months ± 19.9, results were analyzed for tumor recurrence, as well as overall and recurrence-free survival time. The Kaplan-Meier method and Cox proportional hazards regression model were used to evaluate the prognostic factors.
Results: The cumulative incidence of local tumor progression (LTP) was 14.5% at 5 years, with tumor size as the only significant predictive factor (relative risk = 2.13, P = .007). Overall 5-year survival and recurrence-free survival rates were 67.9% and 25.9%, respectively. Significant predictive factors for poor overall survival were Child-Pugh class B (relative risk = 2.43, P = .011), serum α-fetoprotein level (relative risk per 100 units = 1.01; P < .001), and presence of portosystemic collaterals (relative risk = 2.15, P = .025). The development of LTP significantly shortened median recurrence-free survival (28.0 months without LTP vs 12.0 months with LTP) and necessitated a higher number of interventional procedures (2.2 sessions without LTP vs 5.1 sessions with LTP).
Conclusion: RFA is a safe and effective first-line treatment for early-stage HCC, with a 5-year survival rate of 67.9%. High serum α-fetoprotein level, advanced Child-Pugh class, and presence of portosystemic collateral vessels had a significant negative effect on overall survival.
RSNA, 2013
Similar articles
-
Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis.Cardiovasc Intervent Radiol. 2014 Jun;37(3):705-15. doi: 10.1007/s00270-013-0708-x. Epub 2013 Aug 3. Cardiovasc Intervent Radiol. 2014. PMID: 23912493
-
Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.Hepatology. 2009 Nov;50(5):1475-83. doi: 10.1002/hep.23181. Hepatology. 2009. PMID: 19731239
-
Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.Jpn J Clin Oncol. 2007 Sep;37(9):658-72. doi: 10.1093/jjco/hym086. Epub 2007 Aug 31. Jpn J Clin Oncol. 2007. PMID: 17766723
-
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097237 Review.
-
Radiofrequency thermal ablation of hepatocellular carcinoma.Dig Dis. 2001;19(4):301-10. doi: 10.1159/000050697. Dig Dis. 2001. PMID: 11935090 Review.
Cited by
-
Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial.Liver Cancer. 2021 Feb;10(1):72-81. doi: 10.1159/000512338. Epub 2020 Dec 8. Liver Cancer. 2021. PMID: 33708641 Free PMC article.
-
Locoregional interventional therapy for hepatocellular carcinoma: radiologic and clinical factors predictive of untreatable progression and time to untreatable progression.Front Pharmacol. 2024 Jul 23;15:1413696. doi: 10.3389/fphar.2024.1413696. eCollection 2024. Front Pharmacol. 2024. PMID: 39108743 Free PMC article.
-
Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities.World J Gastroenterol. 2022 Jul 28;28(28):3573-3585. doi: 10.3748/wjg.v28.i28.3573. World J Gastroenterol. 2022. PMID: 36161045 Free PMC article. Review.
-
How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles.Cancers (Basel). 2023 Feb 19;15(4):1324. doi: 10.3390/cancers15041324. Cancers (Basel). 2023. PMID: 36831664 Free PMC article. Review.
-
Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.Eur Radiol. 2019 Jun;29(6):3122-3131. doi: 10.1007/s00330-018-5941-x. Epub 2019 Jan 14. Eur Radiol. 2019. PMID: 30643939
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical